Article History
Received: 31 December 2020
Revised: 22 April 2021
Accepted: 5 May 2021
First Online: 27 May 2021
Conflict of interest
: N.D. has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE, Amgen, Novimmune, Glycomimetics, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, and Agios. F.R. has received research funding from Astellas, and Novartis and has served as a member of advisory board in Astellas and Novartis. S.V. has nothing to disclose.